UAE’s EDE eliminates medical monopolies with new multi-agent mandate

UAE—The Emirates Drug Establishment (EDE) has launched a groundbreaking mechanism to dismantle monopolies on medical products in the UAE.

Pharmaceutical companies must now appoint more than one authorized agent for each product they market.

EDE activated this rule under Federal Decree-Law No. (38) of 2024, which governs medical products, pharmacists, and pharmaceutical establishments.

This step supports the UAE’s goals to bolster national readiness, secure pharmaceutical supplies, and guarantee steady access to medicines nationwide.

It also makes the business environment more investor-friendly, heightens global competitiveness, and expands treatment choices for various conditions.

Tackling supply risks and enhancing flexibility

For the first time in the UAE, this mechanism curbs monopolies and reduces risks from emergencies or operational hiccups.

It ensures continuous availability of medical products to meet patient and healthcare facility needs around the clock.

The change boosts supply chain flexibility, allowing quicker responses to demand shifts and public health crises.

It improves distribution through smarter inventory management and faster delivery across all emirates.

Additionally, it diversifies channels, prevents control over quantities or timing, spurs competition among pharma firms and logistics providers, and elevates standards in quality, storage, and transport.

Leaders champion pharmaceutical ecosystem growth

H.E. Saeed bin Mubarak Al Hajeri, Minister of State and EDE Board Chairman, described the mechanism as central to the UAE’s strategy for a resilient national pharmaceutical ecosystem.

It adapts to health and economic changes by diversifying supply chains, streamlining regulations, and creating flexible laws that sustain the market and protect public health.

Al Hajeri stressed that reliable medicine access strengthens drug security, a key part of overall health protection.

He highlighted pharmaceutical investment as a UAE strength, drawing regional and global funds thanks to advanced infrastructure and modern rules.

These enable global companies to set up regional hubs and produce innovative and generic drugs locally.

UAE leaders remain dedicated to fostering innovation and investment in healthcare, especially pharmaceuticals.

H.E. Fatima Al Kaabi, EDE Director General, noted that the rule regulates distribution, sharpens supply management, and builds adaptability to health challenges.

It stabilizes and sustains the market, aligning with global best practices.

Al Kaabi affirmed the UAE’s prime position for pharma industry growth and a leap in investments.

EDE prioritizes medical manufacturing and R&D in its strategy, committed to top-quality healthcare and pharmaceutical security—even in crises.